AbbVie ends 11-year Calico partnership focused on aging research
FierceBiotech - 12-Nov-2025AbbVie ends its $1.75B Calico deal after the ALS drug fosigotifator failed in phase 2/3 trials
Join the club for FREE to access the whole archive and other member benefits.
Pharmaceutical research and development.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
Visit website: https://www.abbvie.com/
Details last updated 05-Mar-2020
AbbVie ends its $1.75B Calico deal after the ALS drug fosigotifator failed in phase 2/3 trials
The pharma giant bets on amylin therapy to enter the weight-loss market
Fosigotifator and DNL343 miss key goals, sparking calls for deeper analysis and longer studies
Aliada’s BBB technology aims to transform CNS drug delivery
Patients’ vision and retinal health remained stable after six months